WEST PHARMACEUTICAL SERVICES, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

						Three Months Ended										Twelve Months Ended
				Dec 31, 2005					Dec 31, 2004					Dec 31, 2005					Dec 31, 2004
Net sales	$	195,600		100	%	$	142,000		100	%	$	699,700		100	%	$	541,600		100	%
Cost of goods sold		143,800		74			103,900		73			507,100		72			385,700		71
Gross profit		51,800		27			38,100		27			192,600		28			155,900		29
Selling, general and administrative expenses		32,400		17			28,000		20			120,300		17			105,200		20
Restructuring and impairment charges		200		—			900		1			(1,300	)	—			1,000		—
Other expense, net		200		—			400		—			1,400		—			1,500		—
Operating profit		19,000		10			8,800		6			72,200		11			48,200		9
Interest expense, net		3,500		2			1,600		1			12,000		2			7,000		1
Income before income taxes		15,500		8			7,200		5			60,200		9			41,200		8
Provision for income taxes		3,100		2			200		—			17,300		3			11,100		2
Minority interests		—		—			—		—			100		—			—		—
Income from consolidated operations		12,400		6	%		7,000		5	%		42,800		6	%		30,100		6	%
Equity in net income of affiliated companies		500					300					2,400					3,400
Income from continuing operations		12,900					7,300					45,200					33,500
Discontinued operations, net of tax		(1,200	)				(6,900	)				400					(14,100	)
Net income	$	11,700				$	400				$	45,600				$	19,400
Net income per share:
Basic:
Continuing operations	$	0.41				$	0.24				$	1.45				$	1.12
Discontinued operations		(0.04	)				(0.23	)				0.01					(0.47	)
	$	0.37				$	0.01				$	1.46				$	0.65
Assuming dilution:
Continuing operations	$	0.39				$	0.23				$	1.39				$	1.09
Discontinued operations		(0.03	)				(0.22	)				0.01					(0.46	)
	$	0.36				$	0.01				$	1.40				$	0.63
Average common shares outstanding		31,433					30,276					31,100					29,955
Average shares assuming dilution		32,810					31,384					32,525					30,842

WEST PHARMACEUTICAL SERVICES

REPORTING SEGMENT INFORMATION

(In thousands)

	Three Months Ended						Twelve Months Ended
	December 31						December 30
Net Sales:	2005			2004			2005			2004
Pharmaceutical Systems	$	136,400		$	124,600		$	538,300		$	481,000
Tech Group		61,400			19,300			170,100			67,900
Eliminations		(2,200	)		(1,900	)		(8,700	)		(7,300	)
Consolidated Total	$	195,600		$	142,000		$	699,700		$	541,600
Operating Profit (Loss):
Pharmaceutical Systems	$	22,200		$	19,200		$	94,000		$	79,100
Tech Group		3,000			600			8,900			3,300
Corporate costs		(3,200	)		(6,900	)		(20,500	)		(23,100	)
Restricted Stock Plan		(1,100	)		(1,900	)		(3,700	)		(5,100	)
Stock Options & Employee Stock Plan		(400	)		—			(2,700	)		—
Restructuring and impairment charges		(200	)		(900	)		1,300			(1,000	)
Domestic pension expense		(1,300	)		(1,300	)		(5,100	)		(5,000	)
Consolidated Total	$	19,000		$	8,800		$	72,200		$	48,200

On August 2, 2005, the Company acquired a 90% interest in Medimop Medical Projects and its U.S. affiliate (Medimop). On February 11, 2005, the Company acquired Monarch Analytical Laboratories, Inc. (Monarch). The results of the Medimop and Monarch businesses are included within the Pharmaceutical Systems Segment. During the three- and twelve-month periods ended December 31, 2005, these businesses contributed $3,600 and $7,700 to net sales and $700 and $1,700 to operating profit, respectively.

On May 20, 2005, the Company completed the acquisition of The Tech Group, Inc. (“TGI”). TGI net sales and operating profit for the period from May 20, 2005 to December 31, 2005 are included in the results under the Tech Group segment for both the three- and twelve-month period ended December 31, 2005. During the three- and twelve-month periods, TGI contributed $42,500 and $98,900 to net sales and $1,700 and $3,500 to operating profit, respectively.

WEST PHARMACEUTICAL SERVICES

REPORTING SEGMENT COMPARISON

(In millions)

					(Including Acquisitions)		(Excluding Acquisitions)
	Pharmaceutical Systems		Tech Group Segment		Consolidated		Consolidated
	Q4 2005	Q4 2004	Q4 2005	Q4 2004	Q4 2005	Q4 2004	Q4 2005	Q4 2004
Net Sales	$136.4	$124.6	$61.4	$ 19.3	$195.6	$ 142.0	$149.5	$142.0
Growth %	9.5%		218.0%		37.9%		5.4%
Gross Profit	$ 44.0	$ 36.2	$ 7.7	$ 1.9	$ 51.8	$ 38.1	$ 44.9	$ 38.1
Gross Margin %	32.3%	29.1%	12.6%	10.0%	26.5%	26.9%	30.0%	26.9%
Operating Profit	$ 22.2	$ 19.2	$ 3.0	$ 0.6	$ 19.0	$ 8.8	$ 16.6	$ 8.8
Operating Margin %	16.3%	15.4%	4.8%	3.2%	9.7%	6.2%	11.1%	6.2%